{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:55:26Z","timestamp":1794484526522,"version":"4.9.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cytogfr.2025.10.009","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:11:45Z","timestamp":1761930705000},"page":"199-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Natural killers or natural regulators? Dual roles of NK cells in checkpoint immunotherapy"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9228-6162","authenticated-orcid":false,"given":"Wenxue","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2025.10.009_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2025.10.009_bib2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/2159-8290.CD-24-1232","article-title":"Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers","volume":"15","author":"Song","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2025.10.009_bib3","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1158\/2159-8290.CD-24-1208","article-title":"Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype","volume":"15","author":"Pozniak","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2025.10.009_bib4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","article-title":"T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy","volume":"4","author":"Melero","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2025.10.009_bib5","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/2159-8290.CD-25-1042","article-title":"The Dark Side of NK Cells in Cancer Immunotherapy","volume":"15","author":"Galvez-Cancino","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2025.10.009_bib6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"Bottcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.10.009_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2025.10.009_bib8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.cytogfr.2025.10.009_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.cytogfr.2025.10.009_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-024-05033-w","article-title":"Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy","volume":"22","author":"Miao","year":"2024","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.cytogfr.2025.10.009_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cytogfr.2025.10.001","article-title":"Reprogramming natural killer cells in the tumor microenvironment: Challenges and therapeuticopportunities","volume":"86","author":"Ma","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2025.10.009_bib12","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells","volume":"175","author":"Andre","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.10.009_bib13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2025.10.009_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104859","article-title":"Metabolic reprogramming of NK cells drives anti-tumor immunity","volume":"215","author":"Yang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cytogfr.2025.10.009_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41467-024-44789-z","article-title":"Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity","volume":"15","author":"Dean","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:29:55Z","timestamp":1781234995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":15,"alternative-id":["S1359610125001431"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.10.009","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural killers or natural regulators? Dual roles of NK cells in checkpoint immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}